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DObjectives: Mitral valve replacement with bioprosthetic valves is becoming more common. The incidence of
structural valve deterioration and the need for reoperative mitral surgery are expected to increase. The operative
mortality and morbidity associated with redo mitral surgery remains high. Transapical transcatheter mitral
valve-in-valve implantation might offer an alternate and safer approach for high-risk patients.
Methods: From July 2007 to April 2010, 11 patients with symptomatic mitral prosthetic valve dysfunction
underwent transapical transapical transcatheter mitral valve-in-valve implantation in our institution. Data
were collected and entered into a database prospectively. The mean age was 81  5 years, with 64% being
female. The mean Society of Thoracic Surgeons risk score was 16.1%  5.8%.
Results: All patients had successful transapical transcatheter mitral valve-in-valve implantation with no 30-day
mortality. One patient died 45 days after surgical intervention from respiratory failure, and 1 patient died on day
135. All other patients were alive and in New York Heart Association class I/II at a median follow-up of
357 days. The median postprocedural transvalvular gradient was 7 mm Hg, and minimal transvalvular or
paravalvular regurgitation was seen.
Conclusions: Transcatheter transapical valve-in-valve implantations into a failed mitral bioprosthesis is techni-
cally feasible with acceptable results. It might be a viable approach for selected high-risk patients. (J Thorac
Cardiovasc Surg 2011;141:711-5)Treatment of valvular heart disease has undergone a major
evolution since the first successful transcatheter aortic valve
implantation (TAVI) by Cribier in 2002.1,2 Better
understanding and refinement in TAVI approaches and
technological advancement of the valve delivery systems
and the commercialization of transcatheter valves in
Europe has led to a rapid expansion of their clinical use in
the treatment of high-risk patients with severe aortic steno-
sis. The early and midterm results of TAVI are promising.3-7
Over the last 2 decades, the clinical use of bioprosthetic
valves in the treatment of valvular heart disease has been
growing. At the same time, there is an expanding population
of complex and high-risk elderly patients who require redo
operations because of structural prosthetic valve dysfunc-
tion. The high morbidity and mortality associated with
reoperative valve surgery in these patients are well recog-
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The Journal of Thoracic and Catechniques, such as transcatheter modality, might well be
the solution for some of these patients. The transcatheter
valve-in-valve implantation (TVIVi) concept has been
shown to be a viable option both in vitro and in animal stud-
ies.11 A direct and coaxial access to the mitral prosthetic
valve can be achieved from the left ventricular apex. We
previously described the first human experience with trans-
apical TVIVi into a failed mitral bioprosthetic valve in an
elderly man with multiple comorbidities.12 We report
a case series of high-risk patients with a failed bioprosthesis
undergoing transcatheter transapical mitral TVIVi with the
Edwards SAPIEN (Edwards Lifesciences, Inc, Irvine, Calif)
balloon-expandable valve stent.MATERIALS AND METHODS
Our patient cohort consisted of patients who underwent transapical
mitral TVIVi in our institution between July 2007 and April 2010. All
patients had previous mitral valve replacement with a biological valve
prosthesis. All patients were symptomatic with severe heart failure and
had documented structural prosthetic valve dysfunctions. Patients were
assessed by our cardiology and cardiac surgery teams and were deemed
unsuitable for reoperative mitral valve surgery because of excessive risk.
Transcatheter valves have been releasedbyHealthCanadaon a compassion-
ate basis to patients who were not candidates for standard therapy. Written
informed consent was obtained from all patients.
Data pertaining to baseline characteristics, procedural details, and out-
comes were prospectively entered in a database. Transthoracic echocardio-
graphic analysis was performed preoperatively, before hospital discharge,
after implantation at 6 and 12 months, and then annually. Clinical follow-
up was performed either by the implanting team or by the local physician.rdiovascular Surgery c Volume 141, Number 3 711
Abbreviations and Acronyms
NYHA ¼ New York Heart Association
TAVI ¼ transcatheter aortic valve implantation
TVIVi ¼ transcatheter valve-in-valve
implantation
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DContinuous variables are described as means  standard deviations,
categorical variables are described by frequencies and percentages, and
the 1-sample Student’s t test was used to compare continuous variables.
All analysis was performed with SPSS version 17.0 software (SPSS, Inc,
Chicago, Ill).
Procedures
The balloon-expandable Cribier–Edwards equine valve was implanted
in our first casewith the 33FAscendra transapical delivery system (Edwards
Lifesciences, Inc). In all subsequent cases the smaller 26F Ascendra
delivery systemwas used to deliver the bovine Edwards SAPIEN prosthesis
(Edwards Lifesciences, Inc).
All operations were performed in our hybrid operating room equipped
with advanced imaging equipment. The technique of transapical mitral
TVIVi was similar to that of transapical TAVI.11,12 Briefly, patients
underwent general anesthesia with single-lumen intubation. A small
anterior thoracotomy at the fifth or sixth intercostal space was performed.
The left ventricular apexwas identified and securedwith 2 octagonal pledg-
eted sutures. The left ventricular apex was punctured, and the mitral
bioprosthesis was easily accessed with a soft J guide wire, followed by
the introduction of a 6F catheter across the mitral bioprosthesis. Subse-
quently, a 0.035-mm Amplatz Extra Stiff wire (Cook Medical, Blooming-
ton, Ind) was exchanged and passed into the left atrium. The 6F catheter
was then upsized to the 26FAscendra I (EdwardsLifesciences, Inc) delivery
system.
Balloon valvuloplasty was not performed, except for the first case, in
which the stenotic mitral prosthesis prevented the retrograde passage of the
Cribier–Edwards valve stent . Valve implantations were aided by 2-dimen-
sional and 3-dimensional transesophageal echocardiographic analysis and
fluoroscopy, and no contrast angiography was required (Figure 1). Measure-
ment of the internal diameter of the mitral bioprosthesis was conducted
intraoperatively, and the appropriately sized SAPIEN valve was prepared.
The precise final positioning and subsequent deployment of the balloon-
expandable valve stent within the failed bioprosthesis was largely guided
by echocardiographic analysis. The role of echocardiographywas paramount
in cases inwhich the pre-existingmitral prosthesis had small or no radiolucent
markers.13 In our experience the placement of the SAPIEN valve 3 to 5 mmFIGURE 1. Mitral valve-in-valve implantation of an Edwards SAPIEN valve
sheath in situ with wire across the valve. B, SAPIEN valve being positioned. C
712 The Journal of Thoracic and Cardiovascular Surgatrially, relative to the sewing cuff of themitral bioprosthesis, provided a very
secure intravalvular fixation and thus minimized the degree of paravalvular
regurgitation. Ventricular tachycardia pacing at a rate of 160 to 200 beats/
min was used during deployment to prevent excessive motion. Echocardio-
graphic analysis was used to confirm valve-in-valve stability and to assess
valvular hemodynamics (Figure 2).RESULTS
Baseline Characteristics
From July 2007 to September 2010, 11 patients underwent
transapical mitral TVIVi procedures in our institution
(Table 1). The mean age of the patients was 81  5 years,
with 64% being female. All patients were symptomatic
with New York Heart Association (NYHA) class III/VI heart
failure. All patients were turned down for conventional redo
mitral valve replacement surgery by our surgeons, with
a mean Society of Thoracic Surgeons risk score of 16.1%
 5.8%. Avariety ofmitral bioprostheses failed in our patient
cohort 7 to 24 years after implantation. The mechanism of
bioprosthetic valvular dysfunction was secondary to severe
mitral regurgitation in 6 and stenosis in 2 patients. Three
patients had combined regurgitation and stenosis. For the 2
patients with severe stenosis, the transvalvular gradients
were 17 and 18mmHg.All patientswere highly symptomatic
from severe heart failure, with 100% being in NYHA class
III/IVat baseline. One patient had ischemic cardiomyopathy
with previous coronary bypass grafting and mitral valve
replacement with a 27-mm Carpentier–Edwards Porcine
valve (Edwards Lifesciences, Inc) and had severe aortic ste-
nosis and severe mitral prosthetic valvular regurgitation.
Prosthetic mitral regurgitation was caused by a perforation
in the leaflet, leading to severe hemolytic anemia, requiring
frequent and repeated packed red blood cells transfusion.
She underwent concomitant transapical aortic valve implan-
tation and TVIVi into the failed mitral bioprosthesis with
two 26-mm SAPIEN valves.Procedural Outcomes
Ourfirst patient hadNYHAclass IV symptoms from severe
mitral prosthetic stenosis and regurgitation. We intended tointo a degenerated Carpentier–Edwards valve. A, Transapical introducer
, SAPIEN valve deployment. D, Final angiographic result.
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FIGURE 2. Three-dimensional transesophageal imaging of a mitral valve-in-valve implantation. A, Before implantation. B, After implantation.
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Ddeliver the equineCribier–Edwardsvalve stent through the left
atrium through a right thoracotomy. However, we failed to
properly align the delivering system to the mitral prosthesis.
Conversion to a left thoracotomy and transapical approach al-
lowed the first successful transcatheter mitral valve-in-valve
procedure.12Theother 10patients hadsuccessful implantation
of the new Edwards SAPIEN valve transapically.
There was no intraprocedural and 30-day mortality. No
apical hemorrhage was encountered, and no reoperation
for bleeding or tamponade was required. In all cases no
hemodynamic compromise was encountered, and support
with cardiopulmonary bypass or conversion to a sternotomy
was not necessary in our cohort. All patients had satisfactory
hemodynamic and valvular function at the end of the proce-
dure (Table 2). Therewere no cases of valve embolization or
malpositioning. No patients had greater than 1þvalvular or
paravalvular regurgitation after implantation. The median
postprocedural transmitral mean gradient was 7.0 mm Hg
(interquartile range, 5–8 mm Hg; Table 2).In-Hospital Course
The first patient had a periprocedural stroke complicated
by in-hospital pneumonia and acute renal failure requiring
temporary hemodialysis. The patient had a prolonged inten-TABLE 1. Baseline characteristics
Age (y)
Valve
age (y)
Baseline
STS score (%)
Baseline
NYHA class t
1 80 7 18.5 III
2 78 11 9.2 III
3 80 13 11.9 IV
4 84 9 19.0 III
5 73 24 18.5 IV
6 77 11 7.3 III
7 84 10 19.1 IV
8 89 11 28.2 IV
9 73 9 15.1 IV
10 76 11 18.2 IV
11 80 10 12.1 III
STS, Society of Thoracic Surgeons; NYHA, New York Heart Association; TVIVi, transcath
The Journal of Thoracic and Casive care unit stay and died on day 45. Therewas no other in-
hospital mortality. One patient required thoracostomy tube
drainage of a hemothorax, and another patient had a small
incisional hematoma.Last Follow-up
Eighty-two percent of patients were alive at a median
follow-up of 357 days (interquartile range, 244–454 days).
The longest follow-up was 669 days. One patient died 135
days after the procedure after admission to the hospital
with pleural effusions and poor mobility. All but 1 patient
were clinically much improved and in NYHA class I/II at
last follow-up. One patient with a concomitant history of
hypertrophic obstructive cardiomyopathy underwent septal
ablation after the procedurewith onlyminimal improvement
in outflow tract gradients and continues to be in NYHA class
III despite satisfactory valve function. One patient had an
atrial clot that was detected on a routine follow-up echocar-
diogram 6 months after TVIVi. The patient was asymptom-
atic and had no embolic events. Patients were treated with
systemic anticoagulation with warfarin and aspirin.
Echocardiographic follow-up demonstrated good valvular
function in all patients, and no structural valve deterioration
was detected.No. of prior
horacotomies Comment
1 Pulmonary hypertension
1 Double valve–combined transapical TVIVi and AVR
1 Alcoholic hepatitis
1 Pulmonary hypertension
2 Coronary artery disease
1 Coronary artery disease
2 Aortic valve re-do, tricuspid annuloplasty
1 Pulmonary hypertension
1 Pulmonary hypertension
Prior AVR
1 Hyptertrophic obstructive cardiomyopathy
1
eter valve-in-valve implantation; AVR, aortic valve replacement.
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TABLE 2. Valve characteristics at baseline and after the procedure
Patient Valve type Valve failure Implanted valve
Baseline mean
gradient
(mm Hg)
Final mean
gradient
(mm Hg)
Baseline
regurgitant
grade
Final
regurgitant
grade
1 Baxter–Edwards, 25 mm
(model 6900P)
Stenosis Edwards SAPIEN, 26 mm 17 6 1þ NA
2 Carpentier–Edwards S.A.V.,
27 mm (model 6650)
Regurgitation Edwards SAPIEN, 26 mm 8 9 4þ 0
3 Carpentier–Edwards S.A.V.,
27 mm (model 6650)
Flail leaflet
regurgitation
Edwards SAPIEN, 26 mm 10 9 4þ 0
4 Medtronic Mosaic, 25 mm
(model 310)
Stenosis Edwards SAPIEN, 26 mm 18 9 1þ 1þ
5 Carpentier–Edwards S.A.V.,
27 mm (model 6650)
Flail leaflets
regurgitation
Edwards SAPIEN, 23 mm 11 8 4þ 1þ
6 Medtronic Intact, 27 mm
(model 705)
Fixed leaflet
regurgitationþstenosis
Edwards SAPIEN, 23 mm 20 7 4þ 0
7 Medtronic Mosaic, 23 mm
(model 305)
Regurgitation Edwards SAPIEN, 23 mm 9 6 4þ 1
8 Carpentier–Edwards Porcine,
29 mm (model 6625)
Regurgitation Edwards SAPIEN, 26 mm 7 3 4þ 0
9 Medtronic Mosaic, 27 mm
(model 310)
Regurgitation Edwards SAPIEN, 26 mm 4 5 4þ 0
10 Edwards Porcine, 25 mm
(model 6900)
Stenosisþ regurgitation Edwards SAPIEN, 23 mm 15 8 3þ 0
11 Medtronic Mosaic, 29 mm
(model 310)
Stenosisþ regurgitation Edwards SAPIEN, 23 mm 12 7 3þ 1
NA, Not applicable.
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DDISCUSSION
Minimally invasive cardiac surgery can be truly achieved
by eliminating the need for cardiopulmonary bypass and
operating through 1 small incision. Catheter-based technolo-
gies enable cardiovascular specialists to treat a variety of
cardiac conditions. In recent years transcatheter therapy for
aortic stenosis provided a great platform for advancement in
catheter-based treatment of other structural valve diseases.
The valve-in-valve concept was demonstrated in vitro and
in animal studies. The initial study in a sheep model by
Walther and colleagues11 proposed a transatrial approach to
the mitral valve. In 2007, our attempt to implant the
Cribier–Edwards valve into a failed Baxter–Edwards porcineFIGURE 3. Valve-in-valve implantation of an Edwards SAPIEN valve into a d
the limited radiolucent markers evident in the Mosaic valve. B, SAPIEN valve po
C, SAPIEN valve deployment. D, Final angiographic result.
714 The Journal of Thoracic and Cardiovascular Surgvalve through the left atrium was unsuccessful. The crossing
and proper alignment of the delivering system to the mitral
prosthesis proved to be extremely difficult. Conversion to
the transapical approach allowed the first known successful
mitral TVIVi. The transapical approach provides direct and
coaxial access to the mitral prosthesis and was used for all
subsequent cases.
In our study fluoroscopy and transesophageal echocar-
diographic analysis was used to position the valve stent
within the mitral prosthesis. However, in cases in which
the prosthesis contained no or minimal radiolucent markers
(Figure 3), transesophageal echocardiographic analysis pro-
vided valuable guidance to properly align the valve stent.egenerated Medtronic Mosaic valve. A, Wire across the Mosaic valve. Note
sitioning. Note the position of the valve relative to the radiolucent markers.
ery c March 2011
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DProper anchoring of the balloon-expandable valve within
the sewing ring of the mitral prosthesis ensured stability
and minimized paravalvular leakage.
The hemodynamic results ofmitral TVIViwere acceptable,
with a residual median gradient of 7.5 mmHg. The transvalv-
ular gradient improved significantly in the 3 patients with
severe stenosis. The residual gradient of 8 mm Hg is not
much different from that seen with the available mitral
bioprostheses. In addition, most of our patients had valvular
insufficiency, and there was no significant valvular or para-
valvular insufficiency in our cohort. All patients had dramatic
improvement in their symptoms and remained inNYHA class
I/II at last follow-up. No structural deterioration was demon-
strated in our relatively short follow-up. Like other biological
prosthesis, these valve stents can be expected to fail in the
future. However, the mode of failure and the long-term
durability of these valve stents remains unknown.
In our limited study, there was no operative mortality, and
86% of our high-risk elderly patients were alive and well at
last follow-up.
CONCLUSIONS
Transapical mitral TVIVi is a feasible and reproducible
procedure. Our early experience with this strategy is encour-
aging. In patients with high or prohibitive risk for reoperative
mitral valve surgery, transapical TVIVi should be considered
as an option.
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Dr Noboru Motomura (Tokyo, Japan). Thank you very much.
I enjoyed it. Just a few quick questions. One is can you do this
procedure again and again like Sapien, in Sapien procedure, in
the future? Second question is, is there any technical difficulty
when the posterior leaflet preservation had been done in the
first-time operation in AVR? Thank you.
Dr Cheung. For your first question, I am Chinese but I am not
a fortune teller; however, I do think that with the low transvalvular
gradient that we have observed with the valve-in-valve procedures,
I think it is possible to perform a second or third transcatheter
valve-in-valve procedure.
The second question was?
Dr Acker.When you leave the subvalvular apparatus, does that
pose a technical challenge?
Dr Cheung. For the second question, 3 of our 8 patients with
previous mitral valve replacement had anterior and posterior leaf-
let preservation. We had no problem accessing mitral prosthesis.
No problem with any guide wire getting caught on any subvalvular
apparatus.
Dr Kristopher Kallin (Los Angeles, Calif). Just a quick ques-
tion about visualizing where you are going to place the valve. Was
this performed in a hybrid type of cardiac OR or were you using
a C-arm?
Dr Cheung. All operations were performed in the hybrid OR
with full catheter lab imaging capability. The placement of the
valve is actually most accurately guided by echocardiography.
Many mitral prostheses do not have radiolucent markers to guide
the implant. Basically, it is best to land the Spaien valve about 3
to 5 mm on the atrial side at the sewing ring and will provide
the best anchorage.rdiovascular Surgery c Volume 141, Number 3 715
